Professor Park Jung-wan of Soonchunhyang University Cheonan Hospital selected a post-doctoral research and growth support project
Jun 04, 2025
Professor Park Jung-wan (Infectious Medicine) of Cheonan Hospital affiliated with Soonchunhyang University was recently selected for the 'Project to Support postdoctoral research and growth of apologists' supported by the Ministry of Health and Welfare.
The project aims to discover promising emerging medical scientists who conduct basic and intermediary research based on clinical experience and to promote creative convergence research through linkage between basic and clinical fields.
In particular, it is focused on linking problems in the clinical field to scientific research and laying the foundation for the development of new treatments.
Professor Park conducts research under the theme of 「Research and Validation of Virus Treatment Candidates through Double-stranded RNA Suppression」 in the project, and will receive 550 million won in research funds until December 2027.
The study plans to develop next-generation antiviral drugs that increase therapeutic effectiveness through double-stranded RNA (Double-stranded RNA) suppression, which plays an important role in viral infection.
Professor Park said, "We plan to present a new paradigm for treating viral diseases and establish a research foundation that can link the possibility of clinical application in the future. As an apologist, we will faithfully serve as a bridge between clinical and basic research.""
The project aims to discover promising emerging medical scientists who conduct basic and intermediary research based on clinical experience and to promote creative convergence research through linkage between basic and clinical fields.
In particular, it is focused on linking problems in the clinical field to scientific research and laying the foundation for the development of new treatments.
Professor Park conducts research under the theme of 「Research and Validation of Virus Treatment Candidates through Double-stranded RNA Suppression」 in the project, and will receive 550 million won in research funds until December 2027.
The study plans to develop next-generation antiviral drugs that increase therapeutic effectiveness through double-stranded RNA (Double-stranded RNA) suppression, which plays an important role in viral infection.
Professor Park said, "We plan to present a new paradigm for treating viral diseases and establish a research foundation that can link the possibility of clinical application in the future. As an apologist, we will faithfully serve as a bridge between clinical and basic research.""
|
This article was translated by Naver AI translator.
